@Article{or.2022.028449, AUTHOR = {YI-NONG CHEN, YING-LIN CHEN, WAN-MING CHEN, MINGCHIH CHEN, BEN-CHANG SHIA, JENQ-YUH KO, SZU-YUAN WU,5,6,7,8,9,10,11}, TITLE = {H1-antihistamine use and head and neck cancer risk in type 2 diabetes mellitus}, JOURNAL = {Oncology Research}, VOLUME = {31}, YEAR = {2023}, NUMBER = {1}, PAGES = {23--34}, URL = {http://www.techscience.com/or/v31n1/51752}, ISSN = {1555-3906}, ABSTRACT = {This study aimed to examine the association between the use of H1-antihistamines (AHs) and head and neck cancer (HNC) risk in patients with type 2 diabetes mellitus (T2DM). Data from the National Health Insurance Research Database of Taiwan were analyzed for the period from 2008 to 2018. A propensity-score-matched cohort of 54,384 patients each in the AH user and nonuser groups was created and analyzed using Kaplan-Meier method and Cox proportional hazards regression. The results showed that the risk of HNC was significantly lower in AH users (adjusted hazard ratio: 0.55, 95% CI: 0.48 to 0.64) and the incidence rate was also lower (5.16 vs. 8.10 per 100,000 person-years). The lower HNC incidence rate in AH users (95% CI: 0.63; 0.55 to 0.73) suggests that AH use may reduce the risk of HNC in T2DM patients.}, DOI = {10.32604/or.2022.028449} }